[go: up one dir, main page]

AR071112A1 - Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.

Info

Publication number
AR071112A1
AR071112A1 ARP090101126A ARP090101126A AR071112A1 AR 071112 A1 AR071112 A1 AR 071112A1 AR P090101126 A ARP090101126 A AR P090101126A AR P090101126 A ARP090101126 A AR P090101126A AR 071112 A1 AR071112 A1 AR 071112A1
Authority
AR
Argentina
Prior art keywords
alkylene
nr10r11
co2h
ch2oh
heterocyclyl
Prior art date
Application number
ARP090101126A
Other languages
English (en)
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of AR071112A1 publication Critical patent/AR071112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Son utiles para inhibir quinasas lipídicas que incluyen p110 alfa y otras isoformas de PI3K, y para tratar trastornos tales como cáncer mediado por quinasas lipídicas. Reivindicacion 1: Un compuesto seleccionado de formula 1 y sus estereoisomeros, isomeros geométricos, tautomeros, o sales aceptables para uso farmacéutico, donde: Z1 es CR1 o N; Z2 es CR2 o N; Z3 es CR3 o N; Z4 es CR4 o N; donde (i) X1 es N y X2 es S, (ii) X1 es S y X2 es N, (iii) X1 es CR7 y X2 es S, o (iv) X1 es S y X2 es CR7; R1, R2, R3, R4, y R7 se seleccionan independientemente entre H, F, CI, Br, I, -CN, -CF3, -CH2OR10, -CH2R10, -alquileno C1-12NR10R11, -alquileno C1-12NR12C(=O)R10, -alquileno C1-12C(=O)OR10, -alquileno C1-12OR10, -CO2R10, -C(=O)N(R10)OR11, -NO2, -NR10R11, -OR10, -S(O)2R10, -C(=O)NR10R11, -C(=O)NR10(alquileno C1-12)NR10R11, -C(=O)NR10(alquileno C1-12)NR10C(=O)OR11, -C(=O)NR10(alquileno C1-12)NR10C(=O)R11, -C(=O)NR10(alquileno C1-12)R10, -C(=NR10)NR10R11, -NR12C(=O)R10, -NR12C(=O)OR11, -NR12C(=O)NR10R11, -NR12C(=O)(alquileno C1-12)NR10R11, -NR12(alquileno C1-12)NR10R11, -NR12(alquileno C1-12)OR10, -NR12(alquileno C1-12)C(=O)NR10R11, -C=CR10, -CH=CHR10, heterociclilo C2-20, heteroarilo C1-20, y fenilo, donde heterociclilo, heteroarilo, y fenilo están opcionalmente sustituidos con uno o más grupos seleccionados entre F, CI, Br, I, -CH2OH, -(CH2)2OH, -CH2CO2H, -CN, -CH2NH2, -(CH2)2N(CH3)2, -CH3, -C(=O)CH3, -C(=O)NHCH3, -CO2H, -CH2CO2CH3, -NH2, -OCH3, -S(O)2CH3, 4-metilpiperazin-1-ilo, y 4-morfolinilo, y donde alquileno está opcionalmente sustituido con uno o más F; A se selecciona entre -C(O)NR5R6, heterociclilo C2-20 y heteroarilo C1-20 donde heterociclilo C2-20 y heteroarilo C1-20 están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2CO2H, -CH(CH3)CH2OCH3, -CN, alquilo C1-12, -alquileno C1-12NR10R11, -alquileno C1-12OR10, -CH3, -C(=O)CH3, -C(=O)NHCH3, -C(=O)N(CH3)2, -CO2H, -CO2CH3, -CH2CO2CH3, -NH2, -NHC(=O)CH3, -OCH3, -S(O)2CH3, 1-metilpiperid-4-ilo, 4-metilpiperazin-1-ilo, 4-morfolinilo, isopropilo, isobutilo, ciclopropilo, ciclopropilmetilo, ciclobutilo, triazolilmetilo, bencilo, y fenilo, donde alquilo, alquileno, bencilo y fenilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CF3, -CH2OH, -CH2CO2H, -CN, -CH2NH2, -CH3, -C(=O)CH3, -C(=O)NHCH3, -CO2H, -CH2CO2CH3, -NH2, -OH, -OCH3, -S(O)2CH3, 1-metilpiperid-4-ilo, (4-metilpiperazin-1-il)carboxamida, -CH2(1H-1,2,4-triazol-5-il), 4-metilpiperazin-1-ilo, y 4-morfolinilo; R5 se selecciona entre H, alquilo C1-12, opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CN, -CO2H, -CONH2, -CONHCH3, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R6 se selecciona entre alquilo C1-12, carbociclilo C3-12, heterociclilo C2-20, heteroarilo C1-20, y arilo C6-20, cada uno opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, - CH2C6H5, -CN, -CF3, -CO2H, -C(=O)NR10R11, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, -S(O)2CH3, -C(=O)NR10(alquileno C1-12)NR10R11, morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-il-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo, S-dioxotiomorfolin-4-ilo, -C:::CR13, -CH=CHR13, y -C(=O)NR10R11 o R5 y R6 junto con el átomo de nitrogeno al cual están unidos forman morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-iI-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo o S-dioxotiomorfolin-4-ilo, cada uno opcionalmente sustituido con uno o más grupos seleccionados entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, - N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R7 se selecciona entre H y F; R10, R11 y R12 se seleccionan independientemente entre H, alquilo C1-12, alquilen C1-12-heterociclilo C2-20, alquilen C1-12-arilo C6-20, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20, donde alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20 están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, 2-oxopirrolidin-1-ilo, -S(O)2NH2, y -S(O)2CH3; o R10 y R11 junto con el átomo de nitrogeno al cual están unidos forman un anillo de heterociclilo C2-20 o heteroarilo C1-20 cada uno opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH3, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, oxo, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; y R13 se selecciona entre H, F, CI, Br, I, -CH3, -CH2CH3, -CN, -CF3, -CH2N(CH3)2, -CH2OH, -CO2H, -CONH2, -CON(CH3)2, -NO2, y -S(O)2CH3. Reivindicacion 32: Un compuesto seleccionado de la formula (2) y sus estereoisomeros, isomeros geométricos, tautomeros, o sales aceptables para uso farmacéutico, donde: R1, R2, R3, y R4 se seleccionan independientemente entre H, F, CI, Br, I, -CN, -CF3, -CH2OR10, -CH2R10, -CH2NR10R11, -(alquileno C1-12)C(=O)OR10, -CO2R10, -C(=O)N(R10)OR11, -NO2, -NR10R11, -OR10, -S(O)2R10, -C(=O)NR10R11, -C(=O)NR10(alquileno C1-12)NR10R11, -C(=O)NR10(alquileno C1-12)NR10C(=O)OR11, -C(=O)NR10(alquileno C1-12)NR10C(=O)R11, -C(=O)NR10(alquileno C1-12)R10, -NR12C(=O)R10, -NR12C(=O)OR11, -NR12C(=O)NR10R11, -NR12(alquileno C1-12)NR10R11, -NR12(alquileno C1-12)OR10, -NR12(alquileno C1-12)C(=O)NR10R11, -C:::CR10, -CH=CHR10, heterociclilo C2-20, heteroarilo C1-20, y fenilo, donde heterociclilo, heteroarilo, y fenilo están opcionalmente sustituidos con uno o más grupos seleccionados entre -CH2OH, -CH2CO2H, -CN, -CH2NH2, -C(=O)CH3, -CO2H, -CH2CO2CH3; -NH2, -S(O)2CH3, 4-metilpiperazin-1-ilo, y 4-morfolinilo; R5 se selecciona entre alquilo C1-12, opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CN, -CO2H, -CONH2, -CONHCH3, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R6 se selecciona entre carbociclilo C3-12, heterociclilo C2-20, heteroarilo C1-20, y arilo C6-20, cada uno opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONHCH3, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, -S(O)2CH3, morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-il-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo, S-dioxotiomorfolin-4-ilo, -C:::CR13, -CH=CHR13, y -C(=O)NR10R11 o R5 y R6 junto con el átomo de nitrogeno al cual están unidos forman morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-iI-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo, S-dioxotiomorfolin-4-ilo, cada uno opcionalmente sustituido con uno o más grupos seleccionados entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, - N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3;cada uno R7 se selecciona independientemente entre H, F, Cl, Br, I, -CH2OH, -CH3, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; o ambos R7 juntos son =O; R8 se selecciona entre H y F; R10, R11 y R12 se seleccionan independientemente entre H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20, donde alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20 están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; o R10 y R11 junto con el átomo de nitrogeno al cual están unidos forman un anillo de heterociclilo C2-20 opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH3, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, oxo, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R13 se selecciona entre H, F, CI, Br, I, -CH3, -CH2CH3, -CN, -CF3, -CH2N(CH3)2, -CH2OH, -CO2H, -CONH2, -CON(CH3)2, -NO2, y -S(O)2CH3; n es 1 o 2; y Y es O, S, N-NR10R11; con las siguientes condiciones: cuando n es 1, Y es O, y R1, R2, R3, R7, R8 son cada uno H, entonces R4 no es H o CH3 y cuando n es 1, entonces ambos R7 en forma conjunta no son =O.
ARP090101126A 2008-03-31 2009-03-30 Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen. AR071112A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4082708P 2008-03-31 2008-03-31
US10222008P 2008-10-02 2008-10-02

Publications (1)

Publication Number Publication Date
AR071112A1 true AR071112A1 (es) 2010-05-26

Family

ID=40790991

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101126A AR071112A1 (es) 2008-03-31 2009-03-30 Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.

Country Status (21)

Country Link
US (4) US7928248B2 (es)
EP (1) EP2276767B1 (es)
JP (1) JP5511786B2 (es)
KR (1) KR101626996B1 (es)
CN (1) CN102333779B (es)
AR (1) AR071112A1 (es)
AU (1) AU2009231885B2 (es)
BR (1) BRPI0910346A2 (es)
CA (1) CA2719032C (es)
CL (1) CL2009000780A1 (es)
DK (1) DK2276767T3 (es)
ES (1) ES2480994T3 (es)
IL (1) IL208359A (es)
MX (1) MX2010010659A (es)
PE (1) PE20091720A1 (es)
PL (1) PL2276767T3 (es)
RU (1) RU2506267C2 (es)
SI (1) SI2276767T1 (es)
TW (1) TWI443102B (es)
WO (1) WO2009123971A1 (es)
ZA (1) ZA201007218B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
PL2276767T3 (pl) 2008-03-31 2014-09-30 Genentech Inc Związki benzopiranowe i benzoksepinowe będące inhibitorami pi3k oraz metody ich stosowania
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
EA201200087A1 (ru) * 2009-07-02 2012-07-30 Новартис Аг 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
RU2557658C2 (ru) * 2009-09-28 2015-07-27 Ф.Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и способы применения
WO2011036280A1 (en) * 2009-09-28 2011-03-31 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
ES2759949T3 (es) * 2009-10-29 2020-05-12 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
JP5735526B2 (ja) 2009-11-13 2015-06-17 メルク セローノ ソシエテ アノニム 三環式ピラゾールアミン誘導体
US9072783B2 (en) 2009-11-18 2015-07-07 Aridis Pharmaceuticals Highly dispersible powders, compositions and methods for preparation
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
UY33671A (es) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
CA2825966A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
DK2705029T3 (en) 2011-05-04 2019-02-18 Rhizen Pharmaceuticals S A Hitherto UNKNOWN RELATIONS AS MODULATORS OF PROTEIN KINASES
HUE043221T2 (hu) * 2011-05-27 2019-08-28 Lexicon Pharmaceuticals Inc Notum pektinacetilészteráz 4H-tieno[3,2-C]kromén-alapú inhibitorai és alkalmazási eljárásaik
KR20140131359A (ko) 2012-02-17 2014-11-12 에프. 호프만-라 로슈 아게 트라이사이클릭 화합물 및 이의 사용 방법
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2014149145A (ru) 2012-05-23 2016-07-20 Ф. Хоффманн-Ля Рош Аг Композиции и способы получения и применения эндодермальных клеток и гепатоцитов
MX357043B (es) 2012-07-04 2018-06-25 Rhizen Pharmaceuticals Sa Inhibidores selectivos de pi3k delta.
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
AR095365A1 (es) 2013-03-13 2015-10-14 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY188946A (en) 2014-12-11 2022-01-14 Natco Pharma Ltd 7-(morpholinyl)-2-(n-piperazinyl methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
PT3277683T (pt) * 2015-03-30 2022-06-28 Jubilant Biosys Ltd Derivados tricíclicos fundidos de 1-(ciclo)alquil piridina-2-ona úteis para o tratamento do cancro
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
JP7029445B2 (ja) 2016-09-02 2022-03-03 ブリストル－マイヤーズ スクイブ カンパニー 置換された三環式ヘテロ環化合物
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
MX2020000690A (es) 2017-07-18 2020-07-29 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
BR112020000962A2 (pt) 2017-07-18 2020-07-14 Nuvation Bio Inc. compostos de 1,8-naftiridinona e usos dos mesmos
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
CN107805255B (zh) * 2017-09-22 2020-06-16 中国药科大学 呋喃[3，2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
CN110467629B (zh) * 2018-05-09 2022-04-08 上海迪诺医药科技有限公司 苯醌衍生物、其药物组合物及应用
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CA3126931A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CN114156414B (zh) * 2021-11-30 2024-05-31 合肥工业大学 一种高效稳定CsPbI3无机钙钛矿电池的制备方法
CN117209457B (zh) * 2022-06-09 2025-08-15 四川师范大学 一种α-手性脒化合物的合成
CN115403591A (zh) * 2022-10-08 2022-11-29 河南师范大学 一种合成萘并噻吩并奥塞平并异喹啉酮类化合物的方法
WO2025082467A1 (zh) * 2023-10-19 2025-04-24 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
DK0638071T3 (da) 1992-12-28 1997-10-27 Eisai Co Ltd Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
US5985799A (en) 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
DE19831878C2 (de) * 1998-07-17 2001-05-17 Aventis Pharma Gmbh Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
WO2002098863A1 (en) * 2001-06-05 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Fused imidazole derivative
CA2492922A1 (en) 2002-07-19 2004-01-29 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004069245A1 (en) 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
CN101039667A (zh) * 2004-10-15 2007-09-19 辉瑞大药厂 双相性精神障碍和相关症状的治疗
RU2281947C1 (ru) * 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
US8877791B2 (en) * 2006-08-04 2014-11-04 Beth Israel Deaconess Medical Center, Inc. Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
PL2276767T3 (pl) 2008-03-31 2014-09-30 Genentech Inc Związki benzopiranowe i benzoksepinowe będące inhibitorami pi3k oraz metody ich stosowania

Also Published As

Publication number Publication date
US20110130363A1 (en) 2011-06-02
CA2719032A1 (en) 2009-10-08
US20130123263A1 (en) 2013-05-16
JP5511786B2 (ja) 2014-06-04
PE20091720A1 (es) 2009-11-26
US7928248B2 (en) 2011-04-19
ES2480994T3 (es) 2014-07-29
CA2719032C (en) 2016-11-08
RU2506267C2 (ru) 2014-02-10
CN102333779A (zh) 2012-01-25
US8399690B2 (en) 2013-03-19
US8846762B2 (en) 2014-09-30
IL208359A (en) 2016-07-31
KR20100137551A (ko) 2010-12-30
AU2009231885B2 (en) 2014-04-03
TW200944531A (en) 2009-11-01
ZA201007218B (en) 2012-06-27
BRPI0910346A2 (pt) 2015-10-06
RU2010143319A (ru) 2012-05-10
EP2276767A1 (en) 2011-01-26
TWI443102B (zh) 2014-07-01
EP2276767B1 (en) 2014-05-07
US9309265B2 (en) 2016-04-12
CN102333779B (zh) 2015-12-09
IL208359A0 (en) 2010-12-30
SI2276767T1 (sl) 2014-08-29
WO2009123971A1 (en) 2009-10-08
PL2276767T3 (pl) 2014-09-30
CL2009000780A1 (es) 2010-01-15
AU2009231885A1 (en) 2009-10-08
JP2011517457A (ja) 2011-06-09
DK2276767T3 (da) 2014-07-14
HK1147741A1 (en) 2011-08-19
KR101626996B1 (ko) 2016-06-02
MX2010010659A (es) 2010-10-26
US20140336154A1 (en) 2014-11-13
US20090247567A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
AR071112A1 (es) Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.
ES2530545T3 (es) Compuestos tricíclicos inhibidores de la PI3K y métodos de uso
AR078187A1 (es) Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
HRP20171453T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20161443A1 (es) Compuestos
ES2855732T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
CL2017001422A1 (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
PE20190475A1 (es) Inhibidores de cdk2/4/6
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
PE20200388A1 (es) Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
PH12016501440A1 (en) Novel heterocyclic compounds
ES2592713T3 (es) Derivados de indazolil-triazol como inhibidores de IRAK
PE20150767A1 (es) Inhibidores de gdf-8
MY193511A (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
PE20160540A1 (es) Inhibidores de bromodominios
PE20160869A1 (es) Derivados novedosos de amino pirimidina
AR064476A1 (es) Derivados de 1h-pirrolo[2, 3-b]piridina sustituidos, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por a-raf, b-raf y/o por c-raf-1.
AR076775A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
AR116880A1 (es) Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm
ECSP11011201A (es) Combinaciones que comprenden metotrexato e inhibidores de dhodh

Legal Events

Date Code Title Description
FC Refusal